EQUITY INVESTMENT (Tables)

9 Months Ended

Mar. 31, 2026

Investments, Debt and Equity Securities [Abstract]

The Company recognized a loss on sale of $201.9 included in Other expense (income), net in the Condensed Consolidated Statements of Operations for the nine months ended March 31, 2026.


Cash proceeds	$	750.0
Wella Distribution Rights	58.0
Total consideration	808.0

Less:
Wella investment carrying value	1,003.0
Transaction and other costs to sell	6.9

Loss on sale of Wella investment	(201.9)

Schedule of equity investments

The Company's equity investment, which is presented within Equity investment in the Condensed Consolidated Balance Sheets, is summarized as follows:


	March 31, 2026		June 30, 2025


Equity investment at fair value:
Wella (a)	—		1,002.0

Total equity investment	$	—	$	1,002.0

(a)As of June 30, 2025, the Company's stake in Wella was 25.84%.

The following table presents summarized financial information of the Company’s equity method investees for the period ending March 31, 2026. Amounts presented represent combined totals at the investee level and not the Company’s proportionate share:


	Three Months Ended March 31,				Nine Months Ended March 31,
	2026		2025		2026		2025
Net revenues	$	—	$	616.3	$	1,526.9	$	2,009.7
Gross profit	$	—	$	426.0	$	1,054.6	$	1,379.1
Operating income	$	—	$	45.3	$	191.8	$	193.1
Income before taxes	$	—	$	—	$	109.3	$	48.8
Net income (loss)	$	—	$	4.2	$	66.0	$	(2.7)

Amounts included for the nine months ending March 31, 2026 related to the investment in Wella include activity through the sale of the Wella investment on December 18, 2025.